Selecting the optimum dose for a new soft gelatin capsule formulation of saquinavir. NV15107 Study Group.

Suppr

超能文献

作者信息

Lalezari J

出版信息

J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Oct 1;19(2):195-7. doi: 10.1097/00042560-199810010-00015.

DOI:10.1097/00042560-199810010-00015

PMID:9768631

Abstract

摘要

相似文献

Selecting the optimum dose for a new soft gelatin capsule formulation of saquinavir. NV15107 Study Group.

J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Oct 1;19(2):195-7. doi: 10.1097/00042560-199810010-00015.

Relationships between exposure to saquinavir monotherapy and antiviral response in HIV-positive patients.HIV 阳性患者中接受沙奎那韦单药治疗与抗病毒反应之间的关系。

Clin Pharmacokinet. 1999 Jul;37(1):75-86. doi: 10.2165/00003088-199937010-00005.

Saquinavir soft-gel capsule formulation. A review of its use in patients with HIV infection.

Drugs. 1998 Mar;55(3):461-86. doi: 10.2165/00003495-199855030-00014.

[The new saquinavir formulation SGC (Soft Gel Capsule)].新型沙奎那韦制剂SGC（软胶囊）

Presse Med. 1999 Apr 17;28(15):815-8.

[Comparison of pharmacokinetics of saquinavir soft-gel capsule (SQV-SGC) combined with ritonavir (RTV), SQV hard-gel capsule with RTV, and SQV-SGC alone].沙奎那韦软胶囊（SQV-SGC）与利托那韦（RTV）联用、沙奎那韦硬胶囊与RTV联用以及单独使用SQV-SGC的药代动力学比较

Kansenshogaku Zasshi. 2003 Jun;77(6):436-42. doi: 10.11150/kansenshogakuzasshi1970.77.436.

NDA submitted for new formulation of saquinavir.已提交沙奎那韦新剂型的新药申请。

AIDS Patient Care STDS. 1997 Aug;11(4):288-9.

Saquinavir as Fortovase: why does it matter?沙奎那韦作为福妥韦：为何重要？

AIDS Clin Care. 1998 May;10(5):37, 40.

Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults.沙奎那韦软胶囊联合洛匹那韦加小剂量利托那韦双重强化方案在成人人类免疫缺陷病毒感染者中的稳态药代动力学。

Antimicrob Agents Chemother. 2004 Nov;48(11):4256-62. doi: 10.1128/AAC.48.11.4256-4262.2004.

Soft gel saquinavir has high exposure.

AIDS Alert. 1997 Dec;12(12):143-4.

Activity of the soft gelatin formulation of saquinavir in combination therapy in antiretroviral-naive patients. NV15355 Study Team.

AIDS. 1998 Jul 30;12(11):F103-9. doi: 10.1097/00002030-199811000-00001.

引用本文的文献

Pharmacokinetics of saquinavir plus low-dose ritonavir in human immunodeficiency virus-infected pregnant women.沙奎那韦联合低剂量利托那韦在人类免疫缺陷病毒感染孕妇中的药代动力学

Antimicrob Agents Chemother. 2004 Feb;48(2):430-6. doi: 10.1128/AAC.48.2.430-436.2004.

Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia.虚拟抑制指数可预测在持续病毒血症的人类免疫缺陷病毒感染患者中，基于茚地那韦的治疗方案加用利托那韦后的疗效。

Antimicrob Agents Chemother. 2002 Dec;46(12):3907-16. doi: 10.1128/AAC.46.12.3907-3916.2002.

Saquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) administration.利托那韦与沙奎那韦（软胶囊）联合给药后沙奎那韦和利托那韦的药代动力学。

Br J Clin Pharmacol. 2001 Sep;52(3):255-64. doi: 10.1046/j.0306-5251.2001.01452.x.

Saquinavir soft gelatin capsule: a comparative safety review.沙奎那韦软明胶胶囊：安全性比较综述。

Drug Saf. 2001;24(3):223-32. doi: 10.2165/00002018-200124030-00005.

Safety and pharmacokinetics of once-daily regimens of soft-gel capsule saquinavir plus minidose ritonavir in human immunodeficiency virus-negative adults.软明胶胶囊沙奎那韦加小剂量利托那韦每日一次给药方案在人类免疫缺陷病毒阴性成年人中的安全性和药代动力学

Antimicrob Agents Chemother. 2000 Oct;44(10):2672-8. doi: 10.1128/AAC.44.10.2672-2678.2000.

Saquinavir soft-gel capsule: an updated review of its use in the management of HIV infection.沙奎那韦软胶囊：其在人类免疫缺陷病毒感染管理中应用的最新综述

Drugs. 2000 Aug;60(2):481-516. doi: 10.2165/00003495-200060020-00016.

Relationships between exposure to saquinavir monotherapy and antiviral response in HIV-positive patients.HIV 阳性患者中接受沙奎那韦单药治疗与抗病毒反应之间的关系。

Clin Pharmacokinet. 1999 Jul;37(1):75-86. doi: 10.2165/00003088-199937010-00005.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验